companydata.dkcompanydata.dk

River Stone Biotech ApS: Financial statements 2024

CVR: 39126729

Source: annual report 2024, Danish Business Authority

01/01/2024 – 31/12/2024

River Stone Biotech ApS (CVR 39126729) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 3,191,557 and a net result of DKK -44,572,973 compared with DKK -72,439,968 the year before. That is a decrease of 7.4% compared with the year before. Equity in the 2024 report amounted to DKK 10,603,157. The solvency ratio was 69%. The company had 23 employees in the financial year.

Gross Profit
DKK 3,191,557
Profit/Loss
DKK -44,572,973
Equity
DKK 10,603,157
Total Assets
DKK 15,359,766
Employees
23

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2024-3.2 mio.-44.6 mio.10.6 mio.23
2023-3.4 mio.-72.4 mio.14.8 mio.22
2022-7.3 mio.-52 mio.10.7 mio.22
2021-7.6 mio.-18.8 mio.-9.8 mio.18
2020-2.5 mio.-16.1 mio.8.9 mio.15

Official annual report

View the official annual report directly on the page with a Pro subscription.

Screen every Danish company

Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.

Try company screening

Events in 2024

River Stone Biotech ApS: The 2023 annual report is outJul 1, 2024

River Stone Biotech ApS has published its annual report for 2023. Gross profit came to DKK 3,445,469, and the net result was DKK -72,439,968.

River Stone Biotech ApS appoints new auditorMay 21, 2024

As of May 21, 2024, Ri Statsautoriseret Revisionspartnerselskab has been appointed auditor of River Stone Biotech ApS.

Auditor steps down at River Stone Biotech ApSMay 20, 2024

As of May 20, 2024, Ri Magnoliavej 12 ApS has stepped down as auditor of River Stone Biotech ApS.

About River Stone Biotech ApS

River Stone Biotech ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2017. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Jørgen Hansen. The board consists of Jørgen Hansen and Paul D. Goldenheim. The company is owned by River Stone Biotech Inc.. The company has 32 employees (2026). In 2025, the company reported a gross profit of DKK 1,169,131 and a net result of DKK -31,204,765 compared with DKK -44,572,973 the year before. Equity in the 2025 report amounted to DKK 7,827,761.

Source: annual report 2025, Danish Business Authority

Other financial years